

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019

PB 114 of 2019

made under subsection 98C(1) of the

National Health Act 1953

**Compilation No. 45**

**Compilation date:** 1 July 2024

**Includes amendments:** F2024L00820

**Registered:** 22 July 2024

**About this compilation**

**This compilation**

This is a compilation of the *National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019* that shows the text of the law as amended and in force on 1 July 2024 (the ***compilation date***).

The notes at the end of this compilation (the ***endnotes***) include information about amending laws and the amendment history of provisions of the compiled law.

**Uncommenced amendments**

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the Register for the compiled law.

**Application, saving and transitional provisions for provisions and amendments**

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

**Editorial changes**

For more information about any editorial changes made in this compilation, see the endnotes.

**Modifications**

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the Register for the compiled law.

**Self‑repealing provisions**

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

Part 1—Preliminary 1

1 Name 1

3 Authority 1

5 Simplified outline of this instrument 1

6 Definitions 1

Part 2—Commonwealth price for pharmaceutical benefits supplied by approved medical practitioners 3

7 Commonwealth price for pharmaceutical benefits supplied by approved medical practitioners 3

Part 3—Conditions on payments for pharmaceutical benefits supplied by approved pharmacists and approved medical practitioners 4

8 Scope of this Part 4

9 Condition on payment for supply of certain pharmaceutical items 4

10 Payment for supply of certain pharmaceutical benefits in complete packs 4

Schedule 1—Ready‑prepared pharmaceutical benefits that are mixtures of ready‑prepared ingredients 5

Schedule 2—Unstable or sterile ingredients used for extemporaneously‑prepared pharmaceutical benefits 7

Schedule 3—Pharmaceutical benefits for which a dangerous drug fee applies 8

Schedule 4—Pharmaceutical benefits to be supplied as complete packs only 13

Schedule 5—Standard formula preparations 29

1 Standard formula preparations 29

Endnotes 31

Endnote 1—About the endnotes 31

Endnote 2—Abbreviation key 32

Endnote 3—Legislation history 33

Endnote 4—Amendment history 40

Part 1—Preliminary

1 Name

 (1) This instrument is the *National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019*.

 (2) This instrument may also be cited as PB 114 of 2019.

3 Authority

 This instrument is made under subsection 98C(1) of the *National Health Act 1953*.

5 Simplified outline of this instrument

The Commonwealth price for pharmaceutical benefits supplied by an approved medical practitioner is worked out in the same way as the Commonwealth price for those benefits supplied by an approved pharmacist.

The Commonwealth will pay an approved medical practitioner or an approved pharmacist for supply of a pharmaceutical benefit only if certain conditions are met. They are as follows:

 (a) if a determination under subsection 85(6) of the Act specifies a brand of the benefit, payment will be made only for supply of that brand of the benefit;

 (b) if the benefit is specified in Schedule 4 to this instrument, payment will be made for supply of the benefit only if it is supplied in a complete pack.

Schedules 1, 2, 3 and 5 list pharmaceutical benefits and ingredients of pharmaceutical benefits for which particular rules apply for working out the Commonwealth price (whether the benefits are supplied by an approved medical practitioner or an approved pharmacist).

Schedule 4 lists pharmaceutical benefits that must be supplied in complete packs by an approved medical practitioner or an approved pharmacist for the practitioner or pharmacist to be paid by the Commonwealth for the supply.

6 Definitions

 In this instrument:

***Act*** means the *National Health Act 1953*.

***approved medical practitioner*** has the meaning given by subsection 84(1) of the Act.

***approved pharmacist*** has the meaning given by subsection 84(1) of the Act.

***brand*** has the meaning given by subsection 84(1) of the Act.

***extemporaneously‑prepared pharmaceutical benefit*** has the meaning given by subsection 6(1) of the *Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020* (PB 66 of 2020).

***listed drug*** has the meaning given by subsection 84(1) of the Act.

***pharmaceutical benefit*** has the meaning given by subsection 84(1) of the Act.

***pharmaceutical item*** has the meaning given by section 84AB of the Act.

Part 2—Commonwealth price for pharmaceutical benefits supplied by approved medical practitioners

7 Commonwealth price for pharmaceutical benefits supplied by approved medical practitioners

 (1) For the purposes of paragraph 98C(1)(a) of the Act, this section provides for the manner of ascertaining the Commonwealth price for a quantity, or number of units, of a pharmaceutical benefit supplied by an approved medical practitioner, for the purposes of a payment to the practitioner in respect of the supply.

 (2) The Commonwealth price is to be ascertained in the same manner as the Commonwealth price for the supply would have been worked out under the *Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020* (PB 66 of 2020) if the supply had been made by an approved pharmacist.

 (3) Schedules 1, 2, 3 and 5 identify pharmaceutical benefits and ingredients in relation to which particular rules for ascertaining the Commonwealth price apply.

Note: Those rules are in the *Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020* (PB 66 of 2020), which is relevant because of subsection (2) of this section.

Part 3—Conditions on payments for pharmaceutical benefits supplied by approved pharmacists and approved medical practitioners

8 Scope of this Part

 For the purposes of paragraph 98C(1)(b) of the Act, this Part sets out the conditions subject to which payments will be made by the Commonwealth in respect of the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners.

9 Condition on payment for supply of certain pharmaceutical items

 If a determination under subsection 85(6) of the Act is in force for a brand of a pharmaceutical item consisting of a drug or medicinal preparation, payments will be made by the Commonwealth in respect of the supply of the drug or preparation only if that brand is supplied.

10 Payment for supply of certain pharmaceutical benefits in complete packs

 Payments will be made by the Commonwealth in respect of the supply of a listed drug in a form described in columns 1 and 2 of an item of Schedule 4 only if the quantity supplied is the quantity contained in a unit of the size described in column 2 of the item (even if the prescription for the supply is for supply of a lesser quantity).

Schedule 1—Ready‑prepared pharmaceutical benefits that are mixtures of ready‑prepared ingredients

Note: See subsection 7(3).

| Ready‑prepared pharmaceutical benefits that are mixtures of ready‑prepared ingredients |
| --- |
| Column 1Listed drug with water purified ‑ BP | Column 2Form |
| Amoxicillin | Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL |
| Amoxicillin | Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL |
| Amoxicillin | Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL |
| Amoxicillin | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL |
| Amoxicillin with clavulanic acid | Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL |
| Amoxicillin with clavulanic acid | Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL |
| Azithromycin | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL |
| Cefaclor | Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL |
| Cefaclor | Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL |
| Cefalexin | Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL |
| Cefalexin | Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL |
| Cefuroxime | Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL (S19A) |
| Clarithromycin | Powder for oral liquid 250 mg per 5 mL, 50 mL |
| Erythromycin | Powder for oral liquid 200 mg (as ethyl succinate) per 5 mL, 100 mL |
| Erythromycin | Powder for oral liquid 400 mg (as ethyl succinate) per 5 mL, 100 mL |
| Flucloxacillin | Powder for oral liquid 125 mg (as sodium monohydrate) per 5 mL, 100 mL |
| Flucloxacillin | Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL |
| Fluconazole | Powder for oral suspension 50 mg in 5 mL, 35 mL |
| Mycophenolic acid | Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL |
| Phenoxymethylpenicillin | Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL |
| Phenoxymethylpenicillin | Powder for oral liquid 250 mg (as potassium) per 5 mL, 100 mL |
| Phenoxymethylpenicillin | Powder for oral liquid 250 mg (as potassium) per 5 mL, 100 mL (s19A) |
| Valganciclovir | Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL |
| Voriconazole | Powder for oral suspension 40 mg per mL, 70 mL |

Schedule 2—Unstable or sterile ingredients used for extemporaneously‑prepared pharmaceutical benefits

Note: See subsection 7(3).

| Unstable or sterile ingredients used for extemporaneously‑prepared pharmaceutical benefits |
| --- |
| Ingredient |
| Water for injections—sterilised |

Schedule 3—Pharmaceutical benefits for which a dangerous drug fee applies

Note: See subsection 7(3).

| Pharmaceutical benefits for which a dangerous drug fee applies |
| --- |
| Column 1Listed drug | Column 2Form |
| Alprazolam | Tablet 250 micrograms |
| Alprazolam | Tablet 500 micrograms |
| Alprazolam | Tablet 1 mg |
| Buprenorphine | Injection (modified release) 8 mg in 0.16 mL pre‑filled syringe |
| Buprenorphine | Injection (modified release) 16 mg in 0.32 mL pre‑filled syringe |
| Buprenorphine | Injection (modified release) 24 mg in 0.48 mL pre‑filled syringe |
| Buprenorphine | Injection (modified release) 32 mg in 0.64 mL pre‑filled syringe |
| Buprenorphine | Injection (modified release) 64 mg in 0.18 mL pre‑filled syringe |
| Buprenorphine | Injection (modified release) 96 mg in 0.27 mL pre‑filled syringe |
| Buprenorphine | Injection (modified release) 100 mg in 0.5 mL pre‑filled syringe |
| Buprenorphine | Injection (modified release) 128 mg in 0.36 mL pre‑filled syringe |
| Buprenorphine | Injection (modified release) 160 mg in 0.45 mL pre‑filled syringe |
| Buprenorphine | Injection (modified release) 300 mg in 1.5 mL pre‑filled syringe |
| Buprenorphine | Tablet (sublingual) 400 micrograms (as hydrochloride) |
| Buprenorphine | Tablet (sublingual) 2 mg (as hydrochloride) |
| Buprenorphine | Tablet (sublingual) 8 mg (as hydrochloride) |
| Buprenorphine | Transdermal patch 5 mg |
| Buprenorphine | Transdermal patch 10 mg |
| Buprenorphine | Transdermal patch 15 mg |
| Buprenorphine | Transdermal patch 20 mg |
| Buprenorphine | Transdermal patch 25 mg |
| Buprenorphine | Transdermal patch 30 mg |
| Buprenorphine | Transdermal patch 40 mg |
| Buprenorphine with naloxone | Film (soluble) 2 mg (as hydrochloride)‑0.5 mg (as hydrochloride) |
| Buprenorphine with naloxone | Film (soluble) 8 mg (as hydrochloride)‑2 mg (as hydrochloride) |
| Codeine | Tablet containing codeine phosphate hemihydrate 30 mg |
| Dexamfetamine | Tablet containing dexamfetamine sulfate 5 mg |
| Fentanyl | Lozenge 200 micrograms (as citrate) |
| Fentanyl | Lozenge 400 micrograms (as citrate) |
| Fentanyl | Lozenge 600 micrograms (as citrate) |
| Fentanyl | Lozenge 800 micrograms (as citrate) |
| Fentanyl | Tablet (orally disintegrating) 100 micrograms (as citrate) |
| Fentanyl | Tablet (orally disintegrating) 200 micrograms (as citrate) |
| Fentanyl | Tablet (orally disintegrating) 400 micrograms (as citrate) |
| Fentanyl | Tablet (orally disintegrating) 600 micrograms (as citrate) |
| Fentanyl | Tablet (orally disintegrating) 800 micrograms (as citrate) |
| Fentanyl | Tablet (sublingual) 100 micrograms (as citrate) |
| Fentanyl | Tablet (sublingual) 200 micrograms (as citrate) |
| Fentanyl | Tablet (sublingual) 300 micrograms (as citrate) |
| Fentanyl | Tablet (sublingual) 400 micrograms (as citrate) |
| Fentanyl | Tablet (sublingual) 600 micrograms (as citrate) |
| Fentanyl | Tablet (sublingual) 800 micrograms (as citrate) |
| Fentanyl | Transdermal patch 1.28 mg |
| Fentanyl | Transdermal patch 2.063 mg |
| Fentanyl | Transdermal patch 2.1 mg |
| Fentanyl | Transdermal patch 2.55 mg |
| Fentanyl | Transdermal patch 4.125 mg |
| Fentanyl | Transdermal patch 4.2 mg |
| Fentanyl | Transdermal patch 5.10 mg |
| Fentanyl | Transdermal patch 7.65 mg |
| Fentanyl | Transdermal patch 8.25 mg |
| Fentanyl | Transdermal patch 8.4 mg |
| Fentanyl | Transdermal patch 10.20 mg |
| Fentanyl | Transdermal patch 12.375 mg |
| Fentanyl | Transdermal patch 12.6 mg |
| Fentanyl | Transdermal patch 16.5 mg |
| Fentanyl | Transdermal patch 16.8 mg |
| Hydromorphone | Injection containing hydromorphone hydrochloride 2 mg in 1 mL |
| Hydromorphone | Injection containing hydromorphone hydrochloride 10 mg in 1 mL |
| Hydromorphone | Oral solution containing hydromorphone hydrochloride 1 mg per mL, 1 mL |
| Hydromorphone | Oral solution containing hydromorphone hydrochloride 1 mg per mL, 1 mL (S19A) |
| Hydromorphone | Oral solution containing hydromorphone hydrochloride 1 mg per mL, 1 mL (S19A) (Pharmascience) |
| Hydromorphone | Tablet containing hydromorphone hydrochloride 2 mg |
| Hydromorphone | Tablet containing hydromorphone hydrochloride 4 mg |
| Hydromorphone | Tablet containing hydromorphone hydrochloride 8 mg |
| Lisdexamfetamine | Capsule containing lisdexamfetamine dimesilate 20 mg |
| Lisdexamfetamine | Capsule containing lisdexamfetamine dimesilate 30 mg |
| Lisdexamfetamine | Capsule containing lisdexamfetamine dimesilate 40 mg |
| Lisdexamfetamine | Capsule containing lisdexamfetamine dimesilate 50 mg |
| Lisdexamfetamine | Capsule containing lisdexamfetamine dimesilate 60 mg |
| Lisdexamfetamine | Capsule containing lisdexamfetamine dimesilate 70 mg |
| Methadone | Injection containing methadone hydrochloride 10 mg in 1 mL |
| Methadone | Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 1 L bottle, 1 mL  |
| Methadone | Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 200 mL bottle, 1 mL |
| Methadone | Tablet containing methadone hydrochloride 10 mg |
| Methylphenidate | Capsule containing methylphenidate hydrochloride 10 mg (modified release) |
| Methylphenidate | Capsule containing methylphenidate hydrochloride 20 mg (modified release) |
| Methylphenidate | Capsule containing methylphenidate hydrochloride 30 mg (modified release) |
| Methylphenidate | Capsule containing methylphenidate hydrochloride 40 mg (modified release) |
| Methylphenidate | Capsule containing methylphenidate hydrochloride 60 mg (modified release) |
| Methylphenidate | Tablet containing methylphenidate hydrochloride 10 mg |
| Methylphenidate | Tablet containing methylphenidate hydrochloride 18 mg (extended release) |
| Methylphenidate | Tablet containing methylphenidate hydrochloride 27 mg (extended release) |
| Methylphenidate | Tablet containing methylphenidate hydrochloride 36 mg (extended release) |
| Methylphenidate | Tablet containing methylphenidate hydrochloride 54 mg (extended release) |
| Morphine | Capsule containing morphine sulfate pentahydrate 10 mg (containing sustained release pellets) |
| Morphine | Capsule containing morphine sulfate pentahydrate 20 mg (containing sustained release pellets) |
| Morphine | Capsule containing morphine sulfate pentahydrate 50 mg (containing sustained release pellets) |
| Morphine | Capsule containing morphine sulfate pentahydrate 100 mg (containing sustained release pellets) |
| Morphine | Capsule containing morphine sulfate pentahydrate 30 mg (controlled release) |
| Morphine | Capsule containing morphine sulfate pentahydrate 60 mg (controlled release) |
| Morphine | Capsule containing morphine sulfate pentahydrate 90 mg (controlled release) |
| Morphine | Capsule containing morphine sulfate pentahydrate 120 mg (controlled release) |
| Morphine | Injection containing morphine hydrochloride trihydrate 10 mg in 1 mL |
| Morphine | Injection containing morphine hydrochloride trihydrate 20 mg in 1 mL |
| Morphine | Injection containing morphine hydrochloride trihydrate 50 mg in 5 mL |
| Morphine | Injection containing morphine hydrochloride trihydrate 100 mg in 5 mL |
| Morphine | Injection containing morphine sulfate pentahydrate 10 mg in 1 mL |
| Morphine | Injection containing morphine sulfate pentahydrate 15 mg in 1 mL |
| Morphine | Injection containing morphine sulfate pentahydrate 30 mg in 1 mL |
| Morphine | Oral solution containing morphine hydrochloride trihydrate 2 mg per mL, 1 mL |
| Morphine | Oral solution containing morphine hydrochloride trihydrate 5 mg per mL, 1 mL |
| Morphine | Oral solution containing morphine hydrochloride trihydrate 5 mg per mL, 1 mL (S19A) |
| Morphine | Oral solution containing morphine hydrochloride trihydrate 10 mg per mL, 1 mL |
| Morphine | Oral solution containing morphine hydrochloride trihydrate 10 mg per mL, 1 mL (RA‑Morph)(S19A) |
| Morphine | Oral solution containing morphine hydrochloride trihydrate 10 mg per mL, 1 mL (S19A) |
| Morphine | Oral solution containing morphine sulfate 2 mg per mL in 100 mL bottle, 1 mL (S19A) |
| Morphine | Oral solution containing morphine sulfate 2 mg per mL in 500 mL bottle, 1 mL (S19A) |
| Morphine | Oral solution containing morphine sulfate 10 mg per 5 mL in 100 mL bottle, 1 mL (S19A) |
| Morphine | Oral solution containing morphine sulfate 10 mg per 5 mL in 300 mL bottle, 1 mL (S19A) |
| Morphine | Tablet containing morphine sulfate pentahydrate 10 mg |
| Morphine | Tablet containing morphine sulfate pentahydrate 20 mg |
| Morphine | Tablet containing morphine sulfate pentahydrate 5 mg (controlled release) |
| Morphine | Tablet containing morphine sulfate pentahydrate 10 mg (controlled release) |
| Morphine | Tablet containing morphine sulfate pentahydrate 15 mg (controlled release) |
| Morphine | Tablet containing morphine sulfate pentahydrate 30 mg (controlled release) |
| Morphine | Tablet containing morphine sulfate pentahydrate 60 mg (controlled release) |
| Morphine | Tablet containing morphine sulfate pentahydrate 100 mg (controlled release) |
| Morphine | Tablet containing morphine sulfate pentahydrate 200 mg (controlled release) |
| Oxycodone | Capsule containing oxycodone hydrochloride 5 mg |
| Oxycodone | Capsule containing oxycodone hydrochloride 10 mg |
| Oxycodone | Capsule containing oxycodone hydrochloride 20 mg |
| Oxycodone | Oral solution containing oxycodone hydrochloride 1 mg per mL, 1 mL |
| Oxycodone | Suppository 30 mg (as pectinate) |
| Oxycodone | Tablet containing oxycodone hydrochloride 5 mg |
| Oxycodone | Tablet containing oxycodone hydrochloride 10 mg (controlled release) |
| Oxycodone | Tablet containing oxycodone hydrochloride 15 mg (controlled release) |
| Oxycodone | Tablet containing oxycodone hydrochloride 20 mg (controlled release) |
| Oxycodone | Tablet containing oxycodone hydrochloride 30 mg (controlled release) |
| Oxycodone | Tablet containing oxycodone hydrochloride 40 mg (controlled release) |
| Oxycodone | Tablet containing oxycodone hydrochloride 80 mg (controlled release) |
| Oxycodone with naloxone | Tablet (controlled release) containing oxycodone hydrochloride 2.5 mg with naloxone hydrochloride 1.25 mg |
| Oxycodone with naloxone | Tablet (controlled release) containing oxycodone hydrochloride 5 mg with naloxone hydrochloride 2.5 mg |
| Oxycodone with naloxone | Tablet (controlled release) containing oxycodone hydrochloride 10 mg with naloxone hydrochloride 5 mg |
| Oxycodone with naloxone | Tablet (controlled release) containing oxycodone hydrochloride 15 mg with naloxone hydrochloride 7.5 mg |
| Oxycodone with naloxone | Tablet (controlled release) containing oxycodone hydrochloride 20 mg with naloxone hydrochloride 10 mg |
| Oxycodone with naloxone | Tablet (controlled release) containing oxycodone hydrochloride 30 mg with naloxone hydrochloride 15 mg |
| Oxycodone with naloxone | Tablet (controlled release) containing oxycodone hydrochloride 40 mg with naloxone hydrochloride 20 mg |
| Oxycodone with naloxone | Tablet (controlled release) containing oxycodone hydrochloride 60 mg with naloxone hydrochloride 30 mg |
| Oxycodone with naloxone | Tablet (controlled release) containing oxycodone hydrochloride 80 mg with naloxone hydrochloride 40 mg |
| Tapentadol | Tablet (modified release) 50 mg (as hydrochloride) |
| Tapentadol | Tablet (modified release) 100 mg (as hydrochloride) |
| Tapentadol | Tablet (modified release) 150 mg (as hydrochloride) |
| Tapentadol | Tablet (modified release) 200 mg (as hydrochloride) |
| Tapentadol | Tablet (modified release) 250 mg (as hydrochloride) |

Schedule 4—Pharmaceutical benefits to be supplied as complete packs only

Note: See section 10.

| Pharmaceutical benefits to be supplied as complete packs only |
| --- |
| Column 1Listed drug | Column 2Form |
| Abiraterone and methylprednisolone | Pack containing 120 tablets abiraterone acetate 125 mg and 30 tablets methylprednisolone 4 mg |
| Abiraterone and methylprednisolone | Pack containing 120 tablets abiraterone acetate 125 mg and 60 tablets methylprednisolone 4 mg |
| Aciclovir | Eye ointment 30 mg per g, 4.5 g |
| Aclidinium | Powder for oral inhalation in breath actuated device 322 micrograms (as bromide) per dose, 60 doses |
| Aclidinium with formoterol | Powder for oral inhalation in breath actuated device containing aclidinium 340 micrograms (as bromide) with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses |
| Adapalene with benzoyl peroxide | Gel 1 mg‑25 mg per g, 30 g |
| Amoxicillin | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL |
| Amoxicillin | Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL |
| Amoxicillin | Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL |
| Amoxicillin | Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL |
| Amoxicillin with clavulanic acid | Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL |
| Amoxicillin with clavulanic acid | Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL |
| Apremilast | Pack containing 4 tablets 10 mg, 4 tablets 20 mg and 19 tablets 30 mg |
| Atenolol | Oral solution 50 mg in 10 mL, 300 mL |
| Atovaquone | Oral suspension 750 mg per 5 mL, 210 mL |
| Atropine | Eye drops containing atropine sulfate monohydrate 10 mg per mL, 15 mL |
| Azithromycin | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL |
| Beclometasone | Pressurised inhalation containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation) |
| Beclometasone | Pressurised inhalation containing beclometasone dipropionate 100 micrograms per dose, 200 doses (CFC‑free formulation) |
| Beclometasone | Pressurised inhalation in breath actuated device containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation) |
| Beclometasone | Pressurised inhalation in breath actuated device containing beclometasone dipropionate 100 micrograms per dose, 200 doses (CFC‑free formulation) |
| Beclometasone with formoterol | Pressurised inhalation containing beclometasone dipropionate 100 micrograms and formoterol fumarate dihydrate 6 micrograms per dose,120 dose |
| Beclometasone with formoterol | Pressurised inhalation containing beclometasone dipropionate 200 micrograms and formoterol fumarate dihydrate 6 micrograms per dose, 120 doses |
| Beclometasone with formoterol and glycopyrronium | Pressurised inhalation containing beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses |
| Beclometasone with formoterol and glycopyrronium | Pressurised inhalation containing beclometasone dipropionate 200 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses |
| Benzydamine | Mouth and throat rinse containing benzydamine hydrochloride 22.5 mg per 15 mL, 500 mL |
| Betaine | Oral powder 180 g |
| Betaxolol | Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL |
| Bimatoprost | Eye drops 300 micrograms per mL, 3 mL |
| Bimatoprost | Eye drops 300 micrograms per mL, single dose units 0.4 mL, 30 |
| Bimatoprost with timolol | Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, 3 mL |
| Bimatoprost with timolol | Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, single dose units 0.4 mL, 30 |
| Bisacodyl | Enemas 10 mg in 5 mL, 25 |
| Brigatinib | Pack containing 7 tablets 90 mg and 21 tablets 180 mg |
| Brimonidine | Eye drops containing brimonidine tartrate 1.5 mg per mL, 5 mL |
| Brimonidine | Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL |
| Brimonidine with timolol | Eye drops containing brimonidine tartrate 2 mg with timolol 5 mg (as maleate) per mL, 5 mL |
| Brinzolamide | Eye drops 10 mg per mL, 5 mL |
| Brinzolamide with brimonidine | Eye drops 10 mg brinzolamide with 2 mg brimonidine tartrate per mL, 5 mL |
| Brinzolamide with timolol | Eye drops 10 mg brinzolamide with timolol 5 mg (as maleate) per mL, 5 mL |
| Budesonide | Nebuliser suspension 500 micrograms in 2 mL single dose units, 30 |
| Budesonide | Nebuliser suspension 1 mg in 2 mL single dose units, 30 |
| Budesonide | Powder for oral inhalation in breath actuated device 100 micrograms per dose, 200 doses |
| Budesonide | Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses |
| Budesonide | Powder for oral inhalation in breath actuated device 400 micrograms per dose, 200 doses |
| Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 100 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses |
| Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 60 doses |
| Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses |
| Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses |
| Budesonide with formoterol | Pressurised inhalation containing budesonide 50 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses |
| Budesonide with formoterol | Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses |
| Budesonide with formoterol | Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses |
| Budesonide with glycopyrronium and formoterol | Pressurised inhalation containing budesonide 160 micrograms with glycopyrronium 7.2 micrograms and formoterol fumarate dihydrate 5 micrograms per dose, 120 doses |
| Buprenorphine | Injection (modified release) 100 mg in 0.5 mL pre‑filled syringe |
| Buprenorphine | Injection (modified release) 300 mg in 1.5 mL pre‑filled syringe |
| Calcipotriol with betamethasone | Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g |
| Calcipotriol with betamethasone | Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g |
| Captopril | Oral solution 5 mg per mL, 95 mL |
| Carbamazepine | Oral suspension 100 mg per 5 mL, 300 mL |
| Carbomer | Eye gel 2 mg per g, 10 g |
| Carmellose | Eye drops containing carmellose sodium 5 mg per mL, 10 mL |
| Carmellose | Eye drops containing carmellose sodium 5 mg per mL, 15 mL |
| Carmellose | Eye drops containing carmellose sodium 10 mg per mL, 15 mL |
| Carmellose with glycerin | Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL |
| Carmustine | Implants 7.7 mg, 8 |
| Cefaclor | Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL |
| Cefaclor | Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL |
| Cefalexin | Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL |
| Cefalexin | Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL |
| Cefuroxime | Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL (S19A) |
| Chloramphenicol | Eye drops 5 mg per mL, 10 mL |
| Chlorpromazine | Oral solution containing chlorpromazine hydrochloride 25 mg per 5 mL, 100 mL |
| Ciclesonide | Pressurised inhalation 80 micrograms per dose, 120 doses (CFC‑free formulation) |
| Ciclesonide | Pressurised inhalation 160 micrograms per dose, 120 doses (CFC‑free formulation) |
| Ciclosporin | Eye drops 1 mg per mL, single dose units 0.3 mL, 30 |
| Ciprofloxacin | Ear drops 3 mg (as hydrochloride) per mL, 5 mL |
| Citrulline | Tablet 1 g, 300 (Citrulline Easy) |
| Clarithromycin | Powder for oral liquid 250 mg per 5 mL, 50 mL |
| Clobetasol | Shampoo containing clobetasol propionate 500 micrograms per mL, 125 mL |
| Clonazepam | Oral liquid 2.5 mg per mL, 10 mL |
| Clozapine | Oral liquid 50 mg per mL, 100 mL |
| Degarelix | Powder for injection 120 mg (as acetate), 2, injection set |
| Desmopressin | Nasal spray (pump pack) containing desmopressin acetate 10 micrograms per actuation, 50 actuations, 5 mL, USP (Apotex) |
| Desmopressin | Nasal spray (pump pack) containing desmopressin acetate 10 micrograms per actuation, 60 actuations, 6 mL |
| Dexamethasone | Eye drops 1 mg per mL, 5 mL |
| Dexamethasone with framycetin and gramicidin | Ear drops containing dexamethasone 500 micrograms (as sodium metasulfobenzoate), framycetin sulfate 5 mg and gramicidin 50 micrograms per mL, 8 mL |
| Diazepam | Oral liquid 10 mg per 10 mL, 100 mL |
| Dorzolamide | Eye drops 20 mg (as hydrochloride) per mL, 5 mL |
| Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL |
| Electrolyte replacement, oral | Oral rehydration salts containing glucose monohydrate 3.56 g, sodium chloride 470 mg, potassium chloride 300 mg and sodium acid citrate 530 mg per sachet, 10 |
| Erythromycin | Powder for oral liquid 200 mg (as ethyl succinate) per 5 mL, 100 mL |
| Erythromycin | Powder for oral liquid 400 mg (as ethyl succinate) per 5 mL, 100 mL |
| Escitalopram | Oral solution 20 mg (as oxalate) per mL, 15 mL |
| Esomeprazole and clarithromycin and amoxicillin | Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate) |
| Esomeprazole and clarithromycin and amoxicillin | Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate) |
| Estradiol | Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28 |
| Estradiol | Transdermal patches 390 micrograms, 8 |
| Estradiol | Transdermal patches 585 micrograms, 8 |
| Estradiol | Transdermal patches 780 micrograms, 8 |
| Estradiol | Transdermal patches 1.17 mg, 8 |
| Estradiol | Transdermal patches 1.56 mg, 8 |
| Estradiol | Transdermal patches 2 mg, 4 |
| Estradiol | Transdermal patches 3.8 mg, 4 |
| Estradiol | Transdermal patches 5.7 mg, 4 |
| Estradiol | Transdermal patches 7.6 mg, 4 |
| Estradiol | Transdermal patches 750 micrograms (as hemihydrate), 8 |
| Estradiol | Transdermal patches 1.5 mg (as hemihydrate), 8 |
| Estradiol | Transdermal patches 3 mg (as hemihydrate), 8 |
| Estradiol and estradiol with dydrogesterone | Pack containing 14 tablets estradiol 1 mg and 14 tablets estradiol 1 mg with dydrogesterone 10 mg |
| Estradiol and estradiol with dydrogesterone | Pack containing 14 tablets estradiol 2 mg and 14 tablets estradiol 2 mg with dydrogesterone 10 mg |
| Estradiol and estradiol with norethisterone | Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate |
| Estradiol and estradiol with norethisterone | Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate |
| Estradiol with norethisterone | Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 |
| Estradiol with norethisterone | Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 |
| Estriol | Pessaries 500 micrograms, 15 |
| Estriol | Vaginal cream 1 mg per g, 15 g |
| Ethosuximide | Oral solution 250 mg per 5 mL, 200 mL |
| Ezetimibe and rosuvastatin | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) |
| Ezetimibe and rosuvastatin | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) |
| Ezetimibe and rosuvastatin | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) |
| Ezetimibe and rosuvastatin | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) |
| Ferrous sulfate | Oral liquid containing 30 mg ferrous sulfate heptahydrate per mL, 250 mL |
| Flucloxacillin | Powder for oral liquid 125 mg (as sodium monohydrate) per 5 mL, 100 mL |
| Flucloxacillin | Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL |
| Fluorometholone | Eye drops 1 mg per mL, 5 mL |
| Fluorometholone | Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL |
| Fluticasone furoate | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms per dose, 30 doses  |
| Fluticasone furoate | Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms per dose, 30 doses  |
| Fluticasone furoate with umeclidinium and vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses |
| Fluticasone furoate with umeclidinium and vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses |
| Fluticasone furoate with vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses |
| Fluticasone furoate with vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses |
| Fluticasone propionate | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses |
| Fluticasone propionate | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses |
| Fluticasone propionate | Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms per dose, 60 doses |
| Fluticasone propionate | Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC‑free formulation) |
| Fluticasone propionate | Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC‑free formulation) |
| Fluticasone propionate | Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC‑free formulation) |
| Fluticasone propionate with formoterol | Pressurised inhalation containing fluticasone propionate 50 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses |
| Fluticasone propionate with formoterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses |
| Fluticasone propionate with formoterol | Pressurised inhalation containing fluticasone propionate 250 micrograms with formoterol fumarate dihydrate 10 micrograms per dose, 120 doses |
| Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses |
| Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses |
| Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses |
| Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) |
| Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) |
| Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) |
| Formoterol | Powder for oral inhalation in breath actuated device containing formoterol fumarate dihydrate 6 micrograms per dose, 60 doses |
| Formoterol | Powder for oral inhalation in breath actuated device containing formoterol fumarate dihydrate 12 micrograms per dose, 60 doses |
| Framycetin | Eye or ear drops containing framycetin sulfate 5 mg per mL, 8 mL |
| Furosemide | Oral solution 10 mg per mL, 30 mL |
| Glyceryl trinitrate | Sublingual spray (pump pack) 400 micrograms per dose, 200 doses |
| Goserelin and bicalutamide | Pack containing 1 subcutaneous implant containing goserelin 3.6 mg (as acetate) in pre‑filled injection syringe and 28 tablets bicalutamide 50 mg |
| Goserelin and bicalutamide | Pack containing 1 subcutaneous implant containing goserelin 10.8 mg (as acetate) in pre‑filled injection syringe and 28 tablets bicalutamide 50 mg |
| Goserelin and bicalutamide | Pack containing 1 subcutaneous implant containing goserelin 10.8 mg (as acetate) in pre‑filled injection syringe and 84 tablets bicalutamide 50 mg |
| Haloperidol | Oral solution 2 mg per mL, 100 mL |
| Hyaluronic acid | Eye drops containing sodium hyaluronate 1 mg per mL, 10 mL |
| Hyaluronic acid | Eye drops containing sodium hyaluronate 2 mg per mL, 10 mL |
| Hydrocortisone | Cream containing hydrocortisone acetate 10 mg per g, 50 g |
| Hydrocortisone | Eye ointment containing hydrocortisone acetate 10 mg per g, 5 g |
| Hydrocortisone | Ointment containing hydrocortisone acetate 10 mg per g, 50 g |
| Hypromellose | 0.3% w/v eye drops, 10 mL (preservative free) |
| Hypromellose | Eye drops 3 mg per mL, 10 mL |
| Hypromellose | Eye drops 5 mg per mL, 15 mL |
| Hypromellose with carbomer 980 | Ocular lubricating gel 3 mg‑2 mg per g, 10 g |
| Hypromellose with dextran | Eye drops containing 3 mg hypromellose 4500 with 1 mg dextran 70 per mL, 15 mL |
| Ketoconazole | Cream 20 mg per g, 30 g |
| Lacosamide | Oral solution 10 mg per mL, 200 mL |
| Larotrectinib | Oral solution 20 mg per mL (as sulfate), 50 mL, 2 |
| Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL |
| Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL |
| Leuprorelin and bicalutamide | Pack containing 1 syringe containing leuprorelin 7.5 mg (as acetate) and 28 tablets bicalutamide 50 mg |
| Leuprorelin and bicalutamide | Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 28 tablets bicalutamide 50 mg |
| Leuprorelin and bicalutamide | Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 84 tablets bicalutamide 50 mg |
| Levetiracetam | Oral solution 100 mg per mL, 300 mL |
| Lumacaftor with ivacaftor | Sachet containing granules, lumacaftor 75 mg and ivacaftor 94 mg |
| Lumacaftor with ivacaftor | Sachet containing granules, lumacaftor 100 mg and ivacaftor 125 mg |
| Lumacaftor with ivacaftor | Sachet containing granules, lumacaftor 150 mg and ivacaftor 188 mg |
| Macrogol 3350 | Powder for oral solution 510 g |
| Macrogol 3350 | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 |
| Mercaptopurine | Oral suspension containing mercaptopurine monohydrate 20 mg per mL, 100 mL |
| Metronidazole | Oral suspension containing metronidazole benzoate 320 mg per 5 mL, 100 mL |
| Metronidazole | Suppositories 500 mg, 10 |
| Miconazole | Cream containing miconazole nitrate 20 mg per g, 30 g |
| Miconazole | Cream containing miconazole nitrate 20 mg per g, 70 g |
| Miconazole | Powder containing miconazole nitrate 20 mg per g, 30 g |
| Miconazole | Tincture 20 mg per mL, 30 mL |
| Mifepristone and misoprostol | Pack containing 1 tablet mifepristone 200 mg and 4 tablets misoprostol 200 micrograms |
| Mupirocin | Nasal ointment 20 mg (as calcium) per g, 3 g |
| Mupirocin | Nasal ointment 20 mg (as calcium) per g, 5 g |
| Mycobacterium bovis (Bacillus Calmette and Guerin (BCG)) Danish 1331 strain | Single dose pack containing powder for irrigation 30 mg, 4 vials |
| Mycophenolic acid | Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL |
| Nafarelin | Nasal spray (pump pack) 200 micrograms (as acetate) per dose, 60 doses |
| Naloxone | Nasal spray 1.8 mg (as hydrochloride dihydrate) in 0.1 mL single dose unit, 2 |
| Naloxone | Nasal spray 1.8 mg (as hydrochloride dihydrate) in 0.1 mL single dose unit, 2 (s19A) |
| Naproxen | Oral suspension 125 mg per 5 mL, 474 mL |
| Netupitant with palonosetron | Capsule containing netupitant 300 mg with palonosetron 500 microgram (as hydrochloride) |
| Nicorandil | Tablets 10 mg, 60 |
| Nicorandil | Tablets 20 mg, 60 |
| Nirmatrelvir and ritonavir | Pack containing 4 tablets nirmatrelvir 150 mg and 2 tablets ritonavir 100 mg, 5 |
| Onasemnogene abeparvovec | Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 3 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 4 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 5 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 6 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 7 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 8 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 3 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 4 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 5 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 6 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 7 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 3 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 4 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 5 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 6 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 7 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 8 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Onasemnogene abeparvovec | Pack containing 9 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL |
| Ondansetron | Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL |
| Oxybutynin | Transdermal patches 36 mg, 8 |
| Ozanimod | Pack containing 4 capsules 230 micrograms and 3 capsules 460 micrograms |
| Paracetamol | Oral liquid 120 mg per 5 mL, 100 mL |
| Paracetamol | Oral liquid 240 mg per 5 mL, 200 mL |
| Paraffin | Eye drops containing liquid paraffin, glycerol, tyloxapol, poloxamer‑188, trometamol hydrochloride, trometamol, cetalkonium chloride, 10 mL (preservative free) |
| Paraffin | Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g |
| Peginterferon beta‑1a | Pack containing single use injection pens containing 63 micrograms in 0.5 mL and 94 micrograms in 0.5 mL |
| Permethrin | Cream 50 mg per g, 30 g |
| Phenytoin | Oral suspension 30 mg per 5 mL, 500 mL |
| Pilocarpine | Eye drops containing pilocarpine hydrochloride 10 mg per mL, 15 mL |
| Pilocarpine | Eye drops containing pilocarpine hydrochloride 20 mg per mL, 15 mL |
| Pilocarpine | Eye drops containing pilocarpine hydrochloride 40 mg per mL, 15 mL |
| Pimecrolimus | Cream 10 mg per g, 15 g |
| Polyethylene glycol 400 with propylene glycol | Eye drops 4 mg‑3 mg per mL, 15 mL |
| Prednisolone | Oral solution 5 mg (as sodium phosphate) per mL, 30 mL |
| Prednisolone with phenylephrine | Eye drops containing prednisolone acetate 10 mg with phenylephrine hydrochloride 1.2 mg per mL, 10 mL |
| Rifampicin | Syrup 100 mg per 5 mL, 60 mL |
| Risdiplam | Powder for oral solution 750 micrograms per mL, 80 mL |
| Risperidone | Oral solution 1 mg per mL, 100 mL |
| Salbutamol | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20 |
| Salbutamol | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20 (S19A) |
| Salbutamol | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30 |
| Salbutamol | Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 20 |
| Salbutamol | Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30 |
| Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation) |
| Salmeterol | Powder for oral inhalation in breath actuated device 50 micrograms (as xinafoate) per dose, 60 doses |
| Semaglutide | Solution for injection 2 mg in 1.5 mL pre‑filled pen |
| Semaglutide | Solution for injection 4 mg in 3 mL pre‑filled pen |
| Silver sulfadiazine | Cream 10 mg per g, 50 g |
| Sirolimus | Oral solution 1 mg per mL, 60 mL |
| Tafluprost | Eye drops 15 micrograms per mL, single dose units 0.3 mL, 30 |
| Testosterone | Transdermal cream 50 mg per mL, 50 mL |
| Testosterone | Transdermal gel 50 mg in 5 g sachet, 30 |
| Testosterone | Transdermal gel (pump pack) 12.5 mg per 1.25 g dose, 60 doses, 2 |
| Testosterone | Transdermal gel (pump pack) 23 mg per 1.15 g dose, 56 doses |
| Theophylline | Oral solution 133.3 mg per 25 mL, 500 mL |
| Timolol | Eye drops 5 mg (as maleate) per mL, 5 mL |
| Timolol | Eye drops (gellan gum solution) 5 mg (as maleate) per mL, 2.5 mL |
| Tiotropium | Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations) |
| Tiotropium with olodaterol | Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses |
| Tobramycin | Eye drops 3 mg per mL, 5 mL |
| Tobramycin | Eye ointment 3 mg per g, 3.5 g |
| Tofacitinib | Oral solution 1 mg per mL, 240 mL |
| Tramadol | Oral drops containing tramadol hydrochloride 100 mg per mL, 10 mL |
| Travoprost | Eye drops 40 micrograms per mL, 2.5 mL |
| Travoprost with timolol | Eye drops 40 micrograms travoprost with timolol 5 mg (as maleate) per mL, 2.5 mL |
| Triamcinolone with neomycin, gramicidin and nystatin | Ear drops containing triamcinolone acetonide 0.9 mg with neomycin 2.25 mg (as sulfate), gramicidin 225 micrograms and nystatin 90,000 units per mL, 7.5 mL |
| Triamcinolone with neomycin, gramicidin and nystatin | Ear ointment containing triamcinolone acetonide 1 mg with neomycin 2.5 mg (as sulfate), gramicidin 250 micrograms and nystatin 100,000 units per g, 5 g |
| Trimethoprim with sulfamethoxazole | Paediatric oral suspension 40 mg‑200 mg per 5 mL, 100 mL |
| Umeclidinium | Powder for oral inhalation in breath actuated device 62.5 micrograms (as bromide) per dose, 30 doses |
| Umeclidinium with vilanterol | Powder for oral inhalation in breath actuated device containing umeclidinium 62.5 micrograms (as bromide) with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses |
| Varenicline | Box containing 11 tablets 0.5 mg (as tartrate) and 14 tablets 1 mg (as tartrate) in the first pack and 28 tablets 1 mg (as tartrate) in the second pack |
| Venetoclax | Pack containing 14 tablets venetoclax 10 mg and 7 tablets venetoclax 50 mg and 7 tablets venetoclax 100 mg and 14 tablets venetoclax 100 mg |

Schedule 5—Standard formula preparations

Note: See subsection 7(3).

1 Standard formula preparations

 Each extemporaneously‑prepared pharmaceutical benefit described in an item of the following table is a standard formula preparation for the purposes of working out the Commonwealth price for supply of the pharmaceutical benefit, unless the benefit:

 (a) varies from what is described in the item because of:

 (i) addition of an ingredient; or

 (ii) omission of an ingredient; or

 (iii) variation of the dose; or

 (b) is a combination of benefits described in 2 or more items of the table.

| Standard formula preparations |
| --- |
| Column 1Form of pharmaceutical benefit | Column 2Standard formula preparation | Column 3Pharmaceutical reference standard |
| Creams | Salicylic Acid and Sulfur Aqueous | APF |
| Ear Drops | Aluminium Acetate | APF |
| Ear Drops | Aluminium Acetate | BP |
| Ear Drops | Sodium Bicarbonate | APF or BP |
| Ear Drops | Spirit | APF |
| Inhalations | Benzoin and Menthol | APF |
| Inhalations | Menthol | APF |
| Inhalations | Menthol and Eucalyptus | BP 1980 |
| Linctuses containing Codeine Phosphate | Codeine | APF |
| Lotions | Aluminium Acetate Aqueous | APF |
| Mixtures, Other | Kaolin | BPC 1968 |
| Mixtures, Other | Magnesium Trisilicate | BPC 1968 |
| Mixtures, Other | Magnesium Trisilicate and Belladonna | BPC 1968 |
| Ointments, Waxes | Benzoic Acid Compound | APF or BP |
| Ointments, Waxes | Boric Acid, Olive Oil and Zinc Oxide | QHF |
| Ointments, Waxes | Salicylic Acid | APF |
| Ointments, Waxes | Salicylic Acid (extemporaneous formula) | BP |
| Paints | Podophyllin Compound | APF 16 or BP |
| Paints | Salicylic Acid | APF |
| Pastes, Other | Zinc | APF or BP |
| Powders for Internal Use | Magnesium Trisilicate | BP |

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

**Abbreviation key—Endnote 2**

The abbreviation key sets out abbreviations that may be used in the endnotes.

**Legislation history and amendment history—Endnotes 3 and 4**

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

**Editorial changes**

The *Legislation Act 2003* authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

**Misdescribed amendments**

A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the *Legislation Act 2003*.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.

Endnote 2—Abbreviation key

|  |  |
| --- | --- |
| ad = added or inserted | o = order(s) |
| am = amended | Ord = Ordinance |
| amdt = amendment | orig = original |
| c = clause(s) | par = paragraph(s)/subparagraph(s) |
| C[x] = Compilation No. x | /sub‑subparagraph(s) |
| Ch = Chapter(s) | pres = present |
| def = definition(s) | prev = previous |
| Dict = Dictionary | (prev…) = previously |
| disallowed = disallowed by Parliament | Pt = Part(s) |
| Div = Division(s) | r = regulation(s)/rule(s) |
| ed = editorial change | reloc = relocated |
| exp = expires/expired or ceases/ceased to have | renum = renumbered |
| effect | rep = repealed |
| F = Federal Register of Legislation | rs = repealed and substituted |
| gaz = gazette | s = section(s)/subsection(s) |
| LA = *Legislation Act 2003* | Sch = Schedule(s) |
| LIA = *Legislative Instruments Act 2003* | Sdiv = Subdivision(s) |
| (md) = misdescribed amendment can be given | SLI = Select Legislative Instrument |
| effect | SR = Statutory Rules |
| (md not incorp) = misdescribed amendment | Sub‑Ch = Sub‑Chapter(s) |
| cannot be given effect | SubPt = Subpart(s) |
| mod = modified/modification | underlining = whole or part not |
| No. = Number(s) | commenced or to be commenced |

Endnote 3—Legislation history

| Name | Registration | Commencement | Application, saving and transitional provisions |
| --- | --- | --- | --- |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019) | 29 Jan 2020 (F2020L00059) | 1 Feb 2020 (s 2(1) item 1) |  |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 1) (PB 22 of 2020) | 31 Mar 2020 (F2020L00358) | 1 Apr 2020 (s 2) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 2) (PB 35 of 2020) | 30 Apr 2020 (F2020L00536) | 1 May 2020 (s 2) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 3) (PB 43 of 2020) | 29 May 2020 (F2020L00644) | 1 June 2020 (s 2) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 4)(PB 57 of 2020) | 30 June 2020 (F2020L00853) | 1 July 2020 (s 2) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 5)(PB 69 of 2020) | 31 July 2020 (F2020L00969) | 1 Aug 2020 (s 2) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 6) (PB 80 of 2020) | 27 Aug 2020 (F2020L01071) | 1 Sept 2020 (s 2) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 7) (PB 104 of 2020) | 30 Oct 2020 (F2020L01371) | 1 Nov 2020 (s 2) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 8) (PB 113 of 2020) | 27 Nov 2020 (F2020L01486) | 1 Dec 2020 (s 2) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 9) (PB 126 of 2020) | 23 Dec 2020 (F2020L01689) | 1 Jan 2021 (s 2) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 1) (PB 15 of 2021) | 25 Feb 2021 (F2021L00154) | 1 Mar 2021 (s 2) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 2) (PB 24 of 2021) | 31 Mar 2021 (F2021L00399) | 1 Apr 2021 (s 2) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 3) (PB 40 of 2021) | 30 Apr 2021 (F2021L00519) | 1 May 2021 (s 2) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 4) (PB 48 of 2021) | 28 May 2021 (F2021L00662) | 1 June 2021 (s 2) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 5) (PB 62 of 2021) | 30 June 2021 (F2021L00905) | 1 July 2021 (s 2) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 6) (PB 76 of 2021) | 31 July 2021 (F2021L01059) | 1 Aug 2021 (s 2) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 7) (PB 89 of 2021) | 31 Aug 2021 (F2021L01216) | 1 Sept 2021 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 8) (PB 99 of 2021) | 30 Sept 2021 (F2021L01350) | 1 Oct 2021 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 9) (PB 111 of 2021) | 31 Oct 2021 (F2021L01493) | 1 Nov 2021 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 1) (PB 25 of 2022) | 31 Mar 2022 (F2022L00450) | 1 Apr 2022 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 2) (PB 35 of 2022) | 29 Apr 2022 (F2022L00645) | 1 May 2022 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 3) (PB 45 of 2022) | 27 May 2022 (F2022L00726) | 1 June 2022 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 4) (PB 56 of 2022) | 29 June 2022 (F2022L00873) | 1 July 2022 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 5) (PB 69 of 2022) | 29 July 2022 (F2022L01021) | 1 Aug 2022 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 6) (PB 87 of 2022) | 30 Sept 2022 (F2022L01305) | 1 Oct 2022 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 7) (PB 101 of 2022) | 31 Oct 2022 (F2022L01411) | 1 Nov 2022 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 113 of 2022) | 30 Nov 2022 (F2022L01547) | 1 Dec 2022 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 9) (PB 122 of 2022) | 23 Dec 2022 (F2022L01756) | 1 Jan 2023 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No.1) (PB 3 of 2023) | 31 Jan 2023 (F2023L00073) | 1 Feb 2023 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No.2) (PB 12 of 2023) | 28 Feb 2023 (F2023L00161) | 1 Mar 2023 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No.3) (PB 23 of 2023) | 31 Mar 2023 (F2023L00388) | 1 Apr 2023 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No.4) (PB 36 of 2023) | 28 Apr 2023 (F2023L00503) | 1 May 2023 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No.5) (PB 45 of 2023) | 31 May 2023 (F2023L00654) | 1 June 2023 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No.6) (PB 56 of 2023) | 30 June 2023 (F2023L00925) | 1 July 2023 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No. 7) (PB 69 of 2023) | 31 July 2023 (F2023L01052) | 1 Aug 2023 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No. 8) (PB 81 of 2023) | 31 Aug 2023 (F2023L01151) | 1 Sept 2023 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No. 9) (PB 93 of 2023) | 29 Sept 2023 (F2023L01335) | 1 Oct 2023 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No. 10) (PB 106 of 2023) | 31 Oct 2023 (F2023L01453) | 1 Nov 2023 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No. 11) (PB 114 of 2023) | 30 Nov 2023 (F2023L01582) | 1 Dec 2023 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No. 12) (PB 130 of 2023) | 22 Dec 2023 (F2023L01749) | 1 Jan 2024 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 1) (PB 3 of 2024) | 31 Jan 2024 (F2024L00123) | 1 Feb 2024 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 2) (PB 17 of 2024) | 29 Feb 2024 (F2024L00240) | 1 Mar 2024 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 3) (PB 28 of 2024) | 28 Mar 2024 (F2024L00409) | 1 Apr 2024 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 4) (PB 41 of 2024) | 30 Apr 2024 (F2024L00500) | 1 May 2024 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 5) (PB 54 of 2024) | 31 May 2024 (F2024L00605) | 1 June 2024 (s 2(1) item 1) | — |
| National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 6) (PB 70 of 2024) | 28 June 2024 (F2024L00820) | 1 July 2024 (s 2(1) item 1) | — |

Endnote 4—Amendment history

| Provision affected | How affected |
| --- | --- |
| **Part 1** |  |
| s 2  | rep LA s 48D |
| s 4  | rep LA s 48C |
| s 6  | am F2020L00853 |
|  | ed C4 |
| **Part 2** |  |
| s 7  | am F2020L00853 |
|  | ed C4 |
| **Schedule 1** |  |
| Schedule 1  | am F2023L00161; F2023L00654; F2023L01335; F2023L01453; F2023L01582; F2024L00500; F2024L00820 |
| **Schedule 3** |  |
| Schedule 3  | am F2020L01071; F2021L00905; F2022L00726; F2022L01021; F2023L00073; F2023L00503; F2023L00925; F2023L01052; F2023L01582; F2023L01749; F2024L00240; F2024L00409; F2024L00820 |
| **Schedule 4** |  |
| Schedule 4  | am F2020L00358; F2020L00536; F2020L00644; F2020L00853; F2020L00969; F2020L01371; F2020L01486; F2020L01689; F2021L00154; F2021L00399; F2021L00519; F2021L00662; F2021L01059; F2021L01216; F2021L01350; F2021L01493; F2022L00450; F2022L00645; F2022L00873; F2022L01021; F2022L01305; F2022L01411; F2022L01547; F2022L01756; F2023L00073; F2023L00161; F2023L00388; F2023L00503; F2023L00654; F2023L00925; F2023L01052; F2023L01151; F2023L01335; F2023L01453; F2023L01582; F2023L01749; F2024L00123; F2024L00240; F2024L00409; F2024L00500; F2024L00605; F2024L00820 |
| **Schedule 5** |  |
| Schedule 5  | am F2021L01059 |
| Schedule 6  | rep LA s 48C |